We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
1176
Supernus Pharmaceuticals
SUPN
$2.78B
$5K ﹤0.01%
182
– –
VERV
1177
DELISTED
Verve Therapeutics
VERV
$5K ﹤0.01%
+141
New +$5.92K
MORF
1178
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5K ﹤0.01%
+108
New +$5.79K
NGM
1179
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5K ﹤0.01%
265
– –
IMGN
1180
DELISTED
Immunogen Inc
IMGN
$5K ﹤0.01%
693
– –
RXDX
1181
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5K ﹤0.01%
+114
New +$3.57K
INBX
1182
DELISTED
Inhibrx, Inc. Common Stock
INBX
$5K ﹤0.01%
+111
New +$4.44K
AMPH icon
1183
Amphastar Pharmaceuticals
AMPH
$903M
$4K ﹤0.01%
165
– –
ARQT icon
1184
Arcutis Biotherapeutics
ARQT
$3.48B
$4K ﹤0.01%
172
– –
ATAI icon
1185
AtaiBeckley Inc
ATAI
$2.65B
$4K ﹤0.01%
+468
New +$5.68K
AVXL icon
1186
Anavex Life Sciences
AVXL
$237M
$4K ﹤0.01%
+222
New +$4.22K
BCYC
1187
Bicycle Therapeutics
BCYC
$279M
$4K ﹤0.01%
+58
New +$3.2K
CHRS icon
1188
Coherus Oncology
CHRS
$227M
$4K ﹤0.01%
262
– –
CRNX icon
1189
Crinetics Pharmaceuticals
CRNX
$8.88B
$4K ﹤0.01%
132
– –
CSTL icon
1190
Castle Biosciences
CSTL
$743M
$4K ﹤0.01%
86
– –
KYNB
1191
Kyntra Bio
KYNB
$28.2M
$4K ﹤0.01%
13
– –
GRFS
1192
Grifois
GRFS
$5.59B
$4K ﹤0.01%
398
– –
MNKD icon
1193
MannKind Corp
MNKD
$1.22B
$4K ﹤0.01%
855
– –
MRUS
1194
DELISTED
Merus
MRUS
$4K ﹤0.01%
+125
New +$3.53K
NRIX icon
1195
Nurix Therapeutics
NRIX
$2.51B
$4K ﹤0.01%
152
– –
PCVX icon
1196
Vaxcyte
PCVX
$7.88B
$4K ﹤0.01%
179
– –
RAPT
1197
DELISTED
RAPT Therapeutics
RAPT
$4K ﹤0.01%
13
– –
REPL icon
1198
Replimune Group
REPL
$430M
$4K ﹤0.01%
160
– –
RNAM
1199
DELISTED
Avidity Biosciences
RNAM
$4K ﹤0.01%
156
– –
SEER icon
1200
Seer Inc
SEER
$115M
$4K ﹤0.01%
+166
New +$4.79K
46 47
48
49 50

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.